Therapeutic solutions ensure good control of cardiovascular diseases and increase patients’ quality of life

According to the data of the National Health Insurance Fund for the third quarter of the last year, Tchaikapharma’s medicinal product “Zornichka” with active ingredient (INN) chlorthalidone marked an increase in the number of packages sold by nearly 95% (compared to the same period in 2023), reaching 40 thousand packages. “Zornicka” belongs to a group of medicines called thiazide diuretics (“dehydrating tablets”).

“Doxazosin-Tchaikapharma also ranks among the top performers with the largest market share in the group of so-called “alpha blockers” used to treat high blood pressure (hypertension) or symptoms due to an enlargement of the prostate gland (benign prostatic hyperplasia ) with more than 62 thousand packs sold.

The huge palette of nearly 50 medicinal products manufactured by Tchaikapharma High Quality Medicines Inc. for the treatment of cardiovascular diseases guarantees a wide therapeutic choice for specialists in the treatment of hypertension, atherosclerosis, dyslipidemias, heart attacks, thrombosis and coronary artery disease. For years, cardiovascular disease has been the number one cause of death in Bulgaria and has been identified as one of the most socially significant diseases due to its high rate of disability and reduced work capacity. For 25 years Tchaikapharma has been improving the quality of life of Bulgarian families by providing affordable modern therapeutic solutions.